Physician profile
Mitchell E Heun
NPI 1750369765
$626.79
in general payments reported to CMS, 2019-2025
28 companies · $32.89 in 2025
The $32.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $27.80 · 2021: $170 · 2022: $13.11 · 2023: $62.01 · 2024: $21.04 · 2025: $32.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $61.80 | 2019-2021 | |
| Allergan, INC. | $46.40 | 2019 | |
| Pfizer INC. | $37.72 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $34.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.46 | 2020-2021 | |
| Biogen, INC. | $30.54 | 2019 | |
| Radius Health, INC. | $29.90 | 2021 | |
| Dexcom, INC. | $25.81 | 2019 | |
| Philips North America LLC | $25.76 | 2019-2021 | |
| Teleflex LLC | $25.75 | 2023 | Urolift |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.96 | 2019-2021 | |
| Axonics, INC. | $21.41 | 2023 | Axonics |
| Abbott Laboratories | $21.04 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $19.23 | 2025 | Inceptiv |
| Ironshore Pharmaceuticals INC. | $18.52 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $15.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.19 | 2019 | |
| Astellas Pharma US INC | $14.85 | 2023 | Myrbetriq |
| Abbvie INC. | $13.66 | 2025 | |
| Amarin Pharma, INC. | $13.65 | 2021 | |
| Genentech USA, INC. | $13.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.02 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.24 | 2019 | |
| Grifols USA, LLC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Heun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.